BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30417211)

  • 21. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
    Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
    J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.
    Massimino M; Bode U; Biassoni V; Fleischhack G
    Expert Opin Biol Ther; 2011 Feb; 11(2):247-56. PubMed ID: 21171927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
    Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
    J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
    Chassot A; Canale S; Varlet P; Puget S; Roujeau T; Negretti L; Dhermain F; Rialland X; Raquin MA; Grill J; Dufour C
    J Neurooncol; 2012 Jan; 106(2):399-407. PubMed ID: 21858607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.
    Fried I; Lossos A; Ben Ami T; Dvir R; Toledano H; Ben Arush MW; Postovski S; Abu Kuidar A; Yalon M; Weintraub M; Benifla M
    J Neurooncol; 2018 Jan; 136(1):189-195. PubMed ID: 29143272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
    Salloum R; DeWire M; Lane A; Goldman S; Hummel T; Chow L; Miles L; Sutton M; Stevenson C; Fouladi M; Leach J
    J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas.
    Gokce-Samar Z; Beuriat PA; Faure-Conter C; Carrie C; Chabaud S; Claude L; Di Rocco F; Mottolese C; Szathmari A; Chabert C; Frappaz D
    Childs Nerv Syst; 2016 Aug; 32(8):1415-23. PubMed ID: 27379495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma.
    Mateos ME; López-Laso E; Izquierdo L; Pérez-Navero JL; García S; Garzás C
    Pediatr Int; 2011 Apr; 53(2):261-3. PubMed ID: 21501315
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
    Izzuddeen Y; Gupta S; Haresh KP; Sharma D; Giridhar P; Rath GK
    J Neurooncol; 2020 Jan; 146(1):91-95. PubMed ID: 31728883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
    Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
    J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
    Shi S; Lu S; Jing X; Liao J; Li Q
    World Neurosurg; 2021 Apr; 148():e565-e571. PubMed ID: 33476781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
    Zaky W; Wellner M; Brown RJ; Blüml S; Finlay JL; Dhall G
    Pediatr Hematol Oncol; 2013 Oct; 30(7):623-32. PubMed ID: 24050762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
    Baxter PA; Su JM; Onar-Thomas A; Billups CA; Li XN; Poussaint TY; Smith ER; Thompson P; Adesina A; Ansell P; Giranda V; Paulino A; Kilburn L; Quaddoumi I; Broniscer A; Blaney SM; Dunkel IJ; Fouladi M
    Neuro Oncol; 2020 Jun; 22(6):875-885. PubMed ID: 32009149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
    Müller K; Schlamann A; Guckenberger M; Warmuth-Metz M; Glück A; Pietschmann S; Wawer A; Kortmann RD; Kramm C; von Bueren AO
    Strahlenther Onkol; 2014 Apr; 190(4):377-81. PubMed ID: 24638239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
    Reyes-Botero G; Laigle-Donadey F; Mokhtari K; Martin-Duverneuil N; Delattre JY
    J Neurooncol; 2014 Dec; 120(3):581-6. PubMed ID: 25139026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
    Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK; Kortmann RD; Pietsch T; Emser A
    Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.
    Xu S; Ramos-Suzarte M; Bai X; Xu B
    Oncotarget; 2016 May; 7(22):33391-407. PubMed ID: 27050148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.